These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 29271268)

  • 21. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.
    Kelly E
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):403-13. PubMed ID: 24909949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
    Rodrigo GJ; Neffen H
    Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
    Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
    Donohue JF; Singh D; Munzu C; Kilbride S; Church A
    Respir Med; 2016 Mar; 112():65-74. PubMed ID: 26797016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. vilanterol + fluticasone (RELVAR Ellipta). Asthma and COPD: yet another beta-2 agonist and corticosteroid combination.
    Prescrire Int; 2016 Apr; 25(170):94. PubMed ID: 27186620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD.
    Caramori G; Chung KF; Adcock IM
    Int J Chron Obstruct Pulmon Dis; 2014; 9():249-56. PubMed ID: 24596460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD.
    Mehta R; Pefani E; Beerahee M; Brealey N; Barnacle H; Birk R; Zhu CQ; Lipson DA
    J Clin Pharmacol; 2018 Nov; 58(11):1461-1467. PubMed ID: 29762864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
    Rodrigo GJ; Neffen H
    Pulm Pharmacol Ther; 2017 Feb; 42():1-6. PubMed ID: 27864038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vilanterol trifenatate for the treatment of COPD.
    Malerba M; Radaeli A; Montuschi P; Morjaria JB
    Expert Rev Respir Med; 2016 Jul; 10(7):719-31. PubMed ID: 27143334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
    Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease?
    Reddy CB; Kanner RE
    Drugs Aging; 2007; 24(8):615-28. PubMed ID: 17702532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bronchodilator combination therapy for the treatment of chronic obstructive pulmonary disease.
    Sethi S; Cote C
    Curr Clin Pharmacol; 2011 Feb; 6(1):48-61. PubMed ID: 21235463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.
    Kankaanranta H; Harju T; Kilpeläinen M; Mazur W; Lehto JT; Katajisto M; Peisa T; Meinander T; Lehtimäki L
    Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):291-307. PubMed ID: 25515181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple inhaled therapy for chronic obstructive pulmonary disease.
    Montuschi P; Malerba M; Macis G; Mores N; Santini G
    Drug Discov Today; 2016 Nov; 21(11):1820-1827. PubMed ID: 27452453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ▼Relvar Ellipta for COPD.
    Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.
    Matera MG; Rogliani P; Rinaldi B; Cazzola M
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):35-41. PubMed ID: 25382021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ; Edin A
    Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.